Compare
Eton Pharmaceuticals, Inc. vs ADC Therapeutics SA vs Arcturus Therapeutics Holdings Inc. vs CytomX Therapeutics, Inc.
| Latest fiscal year | Eton Pharmaceuticals, Inc. ETON | ADC Therapeutics SA ADCT | Arcturus Therapeutics Holdings Inc. ARCT | CytomX Therapeutics, Inc. CTMX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $79.95M | $81.36M | $82.03M | $76.20M |
| Revenue growth (YoY) | +104.9% | +14.9% | -46.1% | -44.8% |
| Gross margin | 53.5% | 92.9% (computed) | n/a | n/a |
| Operating margin | -1.1% | -149.3% | -93.0% | -29.3% |
| Net margin | -5.8% | -175.3% | -80.2% | -22.8% |
| Net income | -$4.60M | -$142.62M | -$65.78M | -$17.37M |
| EPS (Diluted) | n/a | -$1.12 | -$2.40 | n/a |
| Operating cash flow | $10.52M | -$141.17M | -$74.27M | -$75.59M |
| Free cash flow | $10.19M | -$141.44M | -$74.50M | -$75.81M |
| Cash & equivalents | $25.94M | $261.34M | $230.91M | $12.67M |
| Total assets | $92.11M | $323.15M | $271.15M | $151.57M |
| Total liabilities | $65.96M | $508.98M | $57.16M | $52.56M |
| Shareholders' equity | $26.15M | -$185.83M | $213.99M | $99.01M |
| Return on year-end equity | -17.6% | n/a | -30.7% | -17.5% |
| Shares outstanding | 27.05M | 125.75M | 28.41M | 170.19M |
Revenue, most recent five fiscal years
| Fiscal year | Eton Pharmaceuticals, Inc. | ADC Therapeutics SA | Arcturus Therapeutics Holdings Inc. | CytomX Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $79.95M Ended 2025-12-31 | $81.36M Ended 2025-12-31 | $82.03M Ended 2025-12-31 | $76.20M Ended 2025-12-31 |
| 1 year earlier | $39.01M Ended 2024-12-31 | $70.84M Ended 2024-12-31 | $152.31M Ended 2024-12-31 | $138.10M Ended 2024-12-31 |
| 2 years earlier | $31.64M Ended 2023-12-31 | $69.56M Ended 2023-12-31 | $166.80M Ended 2023-12-31 | $101.21M Ended 2023-12-31 |
| 3 years earlier | $21.25M Ended 2022-12-31 | $209.91M Ended 2022-12-31 | $206.00M Ended 2022-12-31 | $53.16M Ended 2022-12-31 |
| 4 years earlier | $21.83M Ended 2021-12-31 | n/a | $12.36M Ended 2021-12-31 | $37.31M Ended 2021-12-31 |